98009351
IPOS COPY
+ IPER
+ Annexes
+ Replacement sheets

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07K 16/28, C12N 15/00, 15/13, A61K 39/395	A1	(11) International Publication Number: WO 97/09351
		(43) International Publication Date: 13 March 1997 (13.03.97)

(21) International Application Number: PCT/US96/14324

(22) International Filing Date: 5 September 1996 (05.09.96)

(30) Priority Data:
08/523,894 6 September 1995 (06.09.95) US

(71) Applicant: IDEC PHARMACEUTICALS CORPORATION [US/US]; 11011 Torreyana Road, San Diego, CA 92121 (US).

(72) Inventors: HANNA, Nabil; 3255 Fortuna Ranch Road, Olivenhain, CA 92024 (US). NEWMAN, Roland, A.; 4311 Robbins Street, San Diego, CA 92122 (US). REFF, Mitchell, E.; 4166 Combe Way, San Diego, CA 92122 (US).

(74) Agents: GESS, E., Joseph et al.; Burns, Doane, Swecker & Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

(57) Abstract

Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing the and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (*in vivo* half-life).